Cargando…

Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors

Muscle resident fibro-adipogenic progenitors (FAPs), support muscle regeneration by releasing cytokines that stimulate the differentiation of myogenic stem cells. However, in non-physiological contexts (myopathies, atrophy, aging) FAPs cause fibrotic and fat infiltrations that impair muscle function...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerquone Perpetuini, Andrea, Giuliani, Giulio, Reggio, Alessio, Cerretani, Mauro, Santoriello, Marisabella, Stefanelli, Roberta, Palma, Alessandro, Vumbaca, Simone, Harper, Steven, Castagnoli, Luisa, Bresciani, Alberto, Cesareni, Gianni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093513/
https://www.ncbi.nlm.nih.gov/pubmed/32210313
http://dx.doi.org/10.1038/s41598-020-62194-6
_version_ 1783510298943029248
author Cerquone Perpetuini, Andrea
Giuliani, Giulio
Reggio, Alessio
Cerretani, Mauro
Santoriello, Marisabella
Stefanelli, Roberta
Palma, Alessandro
Vumbaca, Simone
Harper, Steven
Castagnoli, Luisa
Bresciani, Alberto
Cesareni, Gianni
author_facet Cerquone Perpetuini, Andrea
Giuliani, Giulio
Reggio, Alessio
Cerretani, Mauro
Santoriello, Marisabella
Stefanelli, Roberta
Palma, Alessandro
Vumbaca, Simone
Harper, Steven
Castagnoli, Luisa
Bresciani, Alberto
Cesareni, Gianni
author_sort Cerquone Perpetuini, Andrea
collection PubMed
description Muscle resident fibro-adipogenic progenitors (FAPs), support muscle regeneration by releasing cytokines that stimulate the differentiation of myogenic stem cells. However, in non-physiological contexts (myopathies, atrophy, aging) FAPs cause fibrotic and fat infiltrations that impair muscle function. We set out to perform a fluorescence microscopy-based screening to identify compounds that perturb the differentiation trajectories of these multipotent stem cells. From a primary screen of 1,120 FDA/EMA approved drugs, we identified 34 compounds as potential inhibitors of adipogenic differentiation of FAPs isolated from the murine model (mdx) of Duchenne muscular dystrophy (DMD). The hit list from this screen was surprisingly enriched with compounds from the glucocorticoid (GCs) chemical class, drugs that are known to promote adipogenesis in vitro and in vivo. To shed light on these data, three GCs identified in our screening efforts were characterized by different approaches. We found that like dexamethasone, budesonide inhibits adipogenesis induced by insulin in sub-confluent FAPs. However, both drugs have a pro-adipogenic impact when the adipogenic mix contains factors that increase the concentration of cAMP. Gene expression analysis demonstrated that treatment with glucocorticoids induces the transcription of Gilz/Tsc22d3, an inhibitor of the adipogenic master regulator PPARγ, only in anti-adipogenic conditions. Additionally, alongside their anti-adipogenic effect, GCs are shown to promote terminal differentiation of satellite cells. Both the anti-adipogenic and pro-myogenic effects are mediated by the glucocorticoid receptor and are not observed in the presence of receptor inhibitors. Steroid administration currently represents the standard treatment for DMD patients, the rationale being based on their anti-inflammatory effects. The findings presented here offer new insights on additional glucocorticoid effects on muscle stem cells that may affect muscle homeostasis and physiology.
format Online
Article
Text
id pubmed-7093513
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70935132020-03-27 Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors Cerquone Perpetuini, Andrea Giuliani, Giulio Reggio, Alessio Cerretani, Mauro Santoriello, Marisabella Stefanelli, Roberta Palma, Alessandro Vumbaca, Simone Harper, Steven Castagnoli, Luisa Bresciani, Alberto Cesareni, Gianni Sci Rep Article Muscle resident fibro-adipogenic progenitors (FAPs), support muscle regeneration by releasing cytokines that stimulate the differentiation of myogenic stem cells. However, in non-physiological contexts (myopathies, atrophy, aging) FAPs cause fibrotic and fat infiltrations that impair muscle function. We set out to perform a fluorescence microscopy-based screening to identify compounds that perturb the differentiation trajectories of these multipotent stem cells. From a primary screen of 1,120 FDA/EMA approved drugs, we identified 34 compounds as potential inhibitors of adipogenic differentiation of FAPs isolated from the murine model (mdx) of Duchenne muscular dystrophy (DMD). The hit list from this screen was surprisingly enriched with compounds from the glucocorticoid (GCs) chemical class, drugs that are known to promote adipogenesis in vitro and in vivo. To shed light on these data, three GCs identified in our screening efforts were characterized by different approaches. We found that like dexamethasone, budesonide inhibits adipogenesis induced by insulin in sub-confluent FAPs. However, both drugs have a pro-adipogenic impact when the adipogenic mix contains factors that increase the concentration of cAMP. Gene expression analysis demonstrated that treatment with glucocorticoids induces the transcription of Gilz/Tsc22d3, an inhibitor of the adipogenic master regulator PPARγ, only in anti-adipogenic conditions. Additionally, alongside their anti-adipogenic effect, GCs are shown to promote terminal differentiation of satellite cells. Both the anti-adipogenic and pro-myogenic effects are mediated by the glucocorticoid receptor and are not observed in the presence of receptor inhibitors. Steroid administration currently represents the standard treatment for DMD patients, the rationale being based on their anti-inflammatory effects. The findings presented here offer new insights on additional glucocorticoid effects on muscle stem cells that may affect muscle homeostasis and physiology. Nature Publishing Group UK 2020-03-24 /pmc/articles/PMC7093513/ /pubmed/32210313 http://dx.doi.org/10.1038/s41598-020-62194-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Cerquone Perpetuini, Andrea
Giuliani, Giulio
Reggio, Alessio
Cerretani, Mauro
Santoriello, Marisabella
Stefanelli, Roberta
Palma, Alessandro
Vumbaca, Simone
Harper, Steven
Castagnoli, Luisa
Bresciani, Alberto
Cesareni, Gianni
Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors
title Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors
title_full Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors
title_fullStr Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors
title_full_unstemmed Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors
title_short Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors
title_sort janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093513/
https://www.ncbi.nlm.nih.gov/pubmed/32210313
http://dx.doi.org/10.1038/s41598-020-62194-6
work_keys_str_mv AT cerquoneperpetuiniandrea januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT giulianigiulio januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT reggioalessio januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT cerretanimauro januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT santoriellomarisabella januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT stefanelliroberta januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT palmaalessandro januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT vumbacasimone januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT harpersteven januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT castagnoliluisa januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT brescianialberto januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors
AT cesarenigianni januseffectofglucocorticoidsondifferentiationofmusclefibroadipogenicprogenitors